National drug policy prices

Abrol, D. Guha, A. (1986) Production and Price Controls The Achilles Heel of National Drug Policy, in Drug Industry and the Indian People, A.S. Gupta (ed.), proceedings and papers presented at the All India Seminar of National Drug Policy, held in New Delhi, on 28 and 29 April 1986, A Delhi Science Forum (DSF) and Federation of Medical Representatives Association of India (FMRAI) publication. 

The precise role of economic evaluation varies among countries. In the vast majority of jurisdictions the role is confined to decisions about pharmaceuticals only, although the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom also considers devices, medical procedures, and public health interventions. Even among those countries considering only pharmaceuticals, there are variations in policy. In some, all new pharmaceuticals are considered, whereas in others only those drugs having a premium price, or likely to have a major impact on the health care system, are evaluated. 

The U.S. Office of National Drug Control Policy (ONDCP) valued the market at US 35 billion in 2000. Since that time, prices have declined and use rates have been fairly stable. See Office of National Drug Control Policy, What America s Users Spend on Illegal Drugs 1988-2000, Washington, D.C. Executive Office of the President, December 2001, p. 14. 

Garber, A. Ed. Berndt is price inflation for the elderly An empirical analysis of prescription drugs. In Frontiers of Health Policy Research, National Bureau of Economic Research Cambridge, MA, 1998. 

In countries, such as some of the member states of the European Community, where social health insurance funds are the largest purchasers of drugs, national reference pricing can have a considerable effect on corporate strategies for R D and on marketing policies. 

Source Office of National Drug Control Policy 2004. The price and purity of illicit drugs 1981 through the second quarter of 2003. 

---